Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018198 · ClinicalTrials.gov registry record
FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test
A clinical trial, sponsored by Rapid Pathogen Screening.
- Completed
- Registry status
- 540
- Enrollment target
NCT02018198: Completed study, sponsored by Rapid Pathogen Screening.
NCT02018198 is a clinical trial that has completed, run by Rapid Pathogen Screening. The registered enrollment target is 540 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02018198 has completed, sponsored by Rapid Pathogen Screening.
- COMPLETED
- Registry status
- 540 participants
- Enrollment target
Study Summary
The aim of this study is to determine performance characteristics of the FebriDx test in predicting viral or bacterial infection etiology among febrile (observed or reported) patients presenting the emergency department, urgent care centers or primary care offices with suspected acute respiratory tract infection.
Primary Outcome
The primary analysis will determine performance characteristics of the FebriDx® test by assessing negative and positive agreement of the FebriDx® results in determining the presence of a bacterial associated systemic host immune response or viral associated systemic host immune response compared with a Clinical Reference Algorithm (comparator method) that is supervised by clinical experts.
Interventions
- DIAGNOSTIC_TEST FebriDx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2021-06-10 |
What the finished NCT02018198 record still lists
NCT02018198 is an observational study that tracks outcomes without assigning an intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which FebriDx is the first listed.
NCT02018198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02018198 about?
NCT02018198 is a clinical study titled "FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test". The aim of this study is to determine performance characteristics of the FebriDx test in predicting viral or bacterial infection etiology among febrile (observed or reported) patients presenting the emergency department, urgent care centers or primary care offices with suspected acute respiratory tr...
What is the current status of trial NCT02018198?
This trial is currently completed. The enrollment target is 540 participants. The study started on 2019-10-15. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT02018198?
The interventions under investigation include: FebriDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02018198?
This trial is sponsored by Rapid Pathogen Screening, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI